Mehta Y S, Jijina F F, Badakere S S, Pathare A V, Mohanty D
Institute of Immunohematology (ICMR), KEM Hospital Campus, Parel, Bombay, India.
Tuber Lung Dis. 1996 Dec;77(6):558-62. doi: 10.1016/s0962-8479(96)90056-8.
Rifampicin-induced thrombocytopenia is reported in three patients with pulmonary tuberculosis. All three patients gave a definite history of having had prior exposure to rifampicin. Immunological studies in all three patients showed the presence of antiplatelet antibodies, resulting in thrombocytopenia. Moreover, binding of these antibodies to the platelet membrane was more avid in the presence of rifampicin, thereby implicating the drug. The avidity of the rifampicin-dependent antibodies was demonstrated by platelet aggregation inhibition test, and estimation of the rifampicin-dependent antibody was done by studying the platelet-associated immunoglobulin [PAlgG] by ELISA which was also used to quantitate antiplatelet antibodies. Immunofluorescence test was also performed to detect antiplatelet antibodies.
据报道，三名肺结核患者出现了利福平诱导的血小板减少症。所有三名患者都有明确的既往接触利福平病史。对所有三名患者的免疫学研究均显示存在抗血小板抗体，导致血小板减少。此外，在有利福平存在的情况下，这些抗体与血小板膜的结合更为紧密，从而表明该药物与此有关。通过血小板聚集抑制试验证明了利福平依赖性抗体的亲和力，并通过酶联免疫吸附测定法（ELISA）研究血小板相关免疫球蛋白（PAlgG）来估计利福平依赖性抗体，ELISA也用于定量抗血小板抗体。还进行了免疫荧光试验以检测抗血小板抗体。
